Yield10 Bioscience Inc
NASDAQ:YTEN
Intrinsic Value
Yield10 Bioscience, Inc. operates as an agricultural bioscience company. [ Read More ]
The intrinsic value of one
YTEN
stock under the Base Case scenario is
14.873
USD.
Compared to the current market price of 0.255 USD,
Yield10 Bioscience Inc
is
Undervalued by 98%.
Yield10 Bioscience Inc's market capitalization is 3.9m USD.
YTEN stock price is 0.255 USD.
YTEN stock price (0.255 USD) is 98% less than its Intrinsic Value (14.873 USD).
YTEN. Open DCF Valuation
YTEN stock price (0.255 USD) is 98% less than its Relative Value (14.873 USD). Open Relative Valuation
YTEN has upside potential of 100% compared to the average analyst price target.
Open Wall St Estimates
YTEN's Revenue has dropped by 87% over the past 12 months.
YTEN's ROE (Return on Equity) has significantly decreased in the last 3 years from -57% to -1 508%, and is approaching profitability.
YTEN's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -176% to -551%, and is approaching profitability.
YTEN has negative Operating Income for the last twelve months.
YTEN has negative Net Income for the last twelve months.
YTEN's ROE (Return on Equity) for the past 12 months is negative and is equal to -1 508%.
YTEN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -551%.
YTEN's long-term liabilties (6m USD) exceed its long-term assets (4m USD).
YTEN's Revenue is forecast to grow at a rate of 669% per year over the next 3 years.
YTEN has negative Free Cash Flow for the last twelve months.
YTEN's Revenue has been falling by 58% per year for the last 3 years.
YTEN's short-term liabilties (5m USD) exceed its short-term assets (1m USD).
YTEN has negative three-year average ROE (Return on Equity): -261%. The company is not efficient at transforming stockholders' equity into net income.
YTEN has negative three-year average ROIC (Return on Invested Capital): -314%. The company is not efficient at using invested capital to generate operating income.
YTEN's D/E (Debt to Equity) is very low and is equal to 0.
YTEN's Altman Z-Score is very low and is equal to -161.61.
YTEN doesn't generate enough operating income (-14m USD) to safely cover interest payments on its debt (68k USD).
Fundamental Analysis
Yield10 Bioscience Inc
Balance Sheet Decomposition
Yield10 Bioscience Inc
| Current Assets | 1.4m |
| Cash & Short-Term Investments | 1.1m |
| Other Current Assets | 332k |
| Non-Current Assets | 2.5m |
| PP&E | 2.2m |
| Other Non-Current Assets | 306k |
| Current Liabilities | 4.9m |
| Accounts Payable | 1.2m |
| Accrued Liabilities | 2.7m |
| Other Current Liabilities | 984k |
| Non-Current Liabilities | 1.5m |
| Other Non-Current Liabilities | 1.5m |
Earnings Waterfall
Yield10 Bioscience Inc
|
Revenue
|
60k
USD
|
|
Operating Expenses
|
-14.5m
USD
|
|
Operating Income
|
-14.4m
USD
|
|
Other Expenses
|
-38k
USD
|
|
Net Income
|
-14.5m
USD
|
Free Cash Flow Analysis
Yield10 Bioscience Inc
What is Free Cash Flow?
YTEN Profitability Score
Profitability Due Diligence
Yield10 Bioscience Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
Score
Yield10 Bioscience Inc's profitability score is 12/100. The higher the profitability score, the more profitable the company is.
YTEN Solvency Score
Solvency Due Diligence
Yield10 Bioscience Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Score
Yield10 Bioscience Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
YTEN Price Targets Summary
Yield10 Bioscience Inc
According to Wall Street analysts, the average 1-year price target for
YTEN
is 0.51 USD
with a low forecast of 0.505 USD and a high forecast of 0.525 USD.
Ownership
YTEN Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
YTEN Price
Yield10 Bioscience Inc
| Average Annual Return | -46.03% |
| Standard Deviation of Annual Returns | 34.35% |
| Max Drawdown | -100% |
| Market Capitalization | 3.9m USD |
| Shares Outstanding | 15 401 700 |
| Percentage of Shares Shorted | 6.31% |
Company Profile
Yield10 Bioscience Inc
Country
Industry
Market Cap
Dividend Yield
Description
Yield10 Bioscience, Inc. operates as an agricultural bioscience company. The company is headquartered in Woburn, Massachusetts and currently employs 29 full-time employees. The company went IPO on 2006-11-10. The firm is developing the oilseed Camelina sativa (Camelina) as a platform crop for large scale production of low-carbon sustainable seed products. The firm focuses on petroleum replacement markets, in which it is developing Camelina oil for use as a biofuel feedstock and polyhydroxyalkanoates (PHA) bioplastics produced in Camelina seed for use as a biodegradable bioplastic; and food and nutrition markets, in which it is developing omega-3 (DHA+EPA) oils produced in Camelina seed for aquaculture, nutraceuticals and protein meal for animal feed markets. The company is engaged in the development of elite Camelina germplasm exhibiting herbicide tolerance, disease resistance and other traits that form improved elite Camelina varieties for the biofuel market. The firm's new seed product traits include the PHA bioplastic trait developed by the Company and the omega-3 (DHA+EPA) oil traits.
You don't have any saved screeners yet
